SAN JOSE, Calif., Aug. 8, 2012/PRNewswire/ -- Ventus Medical announces the publication of clinical trial data for its new Theravent Advanced Nightly Snore Therapy in Sleep Diagnosis and Therapy, a medical journal for sleep professionals
The randomized, controlled trial of 49 patients demonstrated that successful users of Theravent averaged a 76% reduction in snoring as assessed using a decibel meter. Additionally, bed partners in the study reported a statistically significant reduction in snoring duration and volume. The study also found that the level of snoring reduction with Theravent was on average about five times that of nasal strips.
"The results of this rigorous study demonstrate very significant improvements in snoring. As a sleep physician, I am delighted and relieved that there is finally a practical snoring treatment that truly works. Theravent should be a welcome option for 45 million snorers in the US and their bed partners who suffer from the effects of snoring," said Philip Westbrook, MD, co-author of the study and Chief Medical Officer of Ventus Medical. "Theravent represents an important, clinically proven option for healthcare providers to recommend to their patients who snore."
Theravent is for people whose snoring affects sleep quality for themselves or their bed partner. Theravent is FDA-cleared and indicated to reduce or eliminate snoring. Theravent uses similar MicroValve Technology first introduced in Ventus Medical's prescription-only Provent Sleep Apnea Therapy. MicroValve Technology has now been proven in more than 15 clinical trials and used for nearly two million nights of sleep. This revolutionary technology increases pressure in the upper airway when a user exhales, creating expiratory positive airway pressure (EPAP), which keeps the airway open and reduces snoring.
